Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Candel Therapeutics, Inc. (CADL)

Candel Therapeutics furnishes investor deck with updated prostate cancer Phase 3 data

Neutral Impact 2 of 5 other Written later

Candel Therapeutics furnished a September 2026 corporate presentation under Regulation FD, for use with investors and analysts. The deck restates Phase 3 results for aglatimagene in localized, intermediate- to high-risk prostate cancer, including extended follow-up data presented at AUA 2026, and reports cash and cash equivalents of $201.6 million as of June 30, 2026. The filing contains no new financial results or guidance.

Key points

  • Phase 3 trial (n=745) met its primary endpoint of disease-free survival, with a hazard ratio of 0.70 (95% CI 0.52 to 0.94; P=0.0155) in the intent-to-treat population.
  • Extended follow-up data (data cutoff March 15, 2026) showed prostate cancer-specific DFS hazard ratio of 0.61 (95% CI 0.44 to 0.85; P=0.0031).
  • Cash and cash equivalents were $201.6 million as of June 30, 2026, with expected runway into Q1 2028.
  • Financing includes a term loan facility with Trinity Capital of up to $130 million (October 2025) and a $100 million royalty funding agreement with RTW Investments (February 2026), subject to approval of aglatimagene in localized prostate c

The filing

CompanyCandel Therapeutics, Inc. (CADL)
Form8-K, current report
Filed with the SECSep 9, 2026, 4:50 PM ET
Accession number0001193125-26-386561

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.